Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir

AIDS

Volumn 22, Issue 10, 2008, Pages 1125-1129

  Sagot Lerolle, Nathalie ^a   Lamine, Aurelia ^a   Chaix, Marie Laure ^b   Boufassa, Faroudy ^a   Aboulker, Jean Paul ^c   Costagliola, Dominique ^a   Goujard, Cécile ^d   Paller, Coralie ^d   Delfraissy, Jean François ^a,d,e   Lambotte, Olivier ^a,d,e  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

CD4 T cells; HIV reservoir; Integrated HIV 1 DNA; Latency; Replication competent virus; Valproic acid

Indexed keywords

ANTIRETROVIRUS AGENT; VALPROIC ACID; VIRUS DNA; VIRUS RNA; ANTICONVULSIVE AGENT; ENZYME INHIBITOR; HISTONE DEACETYLASE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEIZURE; TREATMENT OUTCOME; VIREMIA; VIROGENESIS; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG ANTAGONISM; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

ADULT; ANTICONVULSANTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PILOT PROJECTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEIZURES; VALPROIC ACID;

EID: 50949096673     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282fd6ddc     Document Type: Article

References (17)

1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
3. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HI V despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295.
4. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53:557-593.
5. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4R T cells using a combination of cytokines.J Exp Med 1998; 188:83-91.
6. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996; 15:1112-1120.
7. Demonte D, Quivy V, Colette Y, Van Lint C. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 2004; 68:1231-1238.
8. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-1108.
9. Lehrman G, HogueIB, PalmerS, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-555.
10. Cohen J. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'. Science 2005; 309:999-1000.
11. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, MargolickJB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833-836.
12. ViardJP, Burgard M, HubertJB, Aaron L, Rabian C, Pertuiset N, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18:45-49.
13. Lambotte O, Chaix ML, Gubler B, Nasserdine N, Wallon C, Goujard C, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18:1147-1158.
14. Brussel A, Sonigo P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J Virol 2003; 77:10119-10124.
15. Demoustier A, Gubler B, Lambotte O, de Goer MG, Wallon C, Goujard C, et al. In patients on prolonged HAART, a significant pool of HIV infected CD4 T cells are HIV-specific. AIDS 2002; 16:1749-1754.
16. Han YW-RM, Yang HC, SilicianoJD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007; 5:95-106.
17. Steel ACS, Teo I, Shaunak S, Nelson M, Gazzard B, Kelleher P. No change to HIV-1 latency with valproate therapy. AIDS 2006; 20:1681-1682.